"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
| Descriptor ID |
D011743
|
| MeSH Number(s) |
D03.383.742
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 6 | 1 | 7 |
| 2010 | 1 | 1 | 2 |
| 2011 | 5 | 1 | 6 |
| 2012 | 2 | 2 | 4 |
| 2013 | 1 | 2 | 3 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 1 | 3 |
| 2016 | 8 | 2 | 10 |
| 2017 | 59 | 43 | 102 |
| 2018 | 63 | 47 | 110 |
| 2019 | 17 | 18 | 35 |
| 2020 | 2 | 21 | 23 |
| 2021 | 10 | 17 | 27 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
Immune thrombocytopenia: options and new perspectives. Blood Coagul Fibrinolysis. 2021 Oct 01; 32(7):427-433.
-
124I-Iodo-DPA-713 Positron Emission Tomography in a Hamster Model of SARS-CoV-2 Infection. Mol Imaging Biol. 2022 02; 24(1):135-143.
-
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep; 22(5):693-707.
-
Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease. J Virol. 2021 10 13; 95(21):e0097521.
-
Audio Interview: Monoclonal Antibodies and Booster Shots. N Engl J Med. 2021 Aug 12; 385(7):e29.
-
The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). Leukemia. 2021 10; 35(10):2917-2923.
-
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. Am J Hematol. 2021 11 01; 96(11):E408-E410.
-
Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1. Muscle Nerve. 2021 10; 64(4):487-490.
-
Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2021 Oct; 99:108027.
-
A Potent Leukocyte Transmigration Blocker: GT-73 Showed a Protective Effect against LPS-Induced ARDS in Mice. Molecules. 2021 Jul 29; 26(15).